A Four-MicroRNA Panel in Serum as a Potential Biomarker for Screening Renal Cell Carcinoma

Li, Rongkang; Lu, Chong; Li, Xinji; Chen, Xuan; Huang, Guoxin; Wen, Zhenyu; Li, Hang; Tao, Lingzhi; Hu, Yimin; Zhao, Zhengping; Chen, Zebo; Lai, Yongqing

doi:10.3389/fgene.2022.897827

Cited by 4 publications

(3 citation statements)

References 59 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the studies, the AUC of a four-miRNA panel for RCC diagnosis, containing miR-1-3p, miR-155-5p, miR-200b-3p, and miR-224-5p, was 0.903 (95% CI: 0.847-0.944; p < 0.001; sensitivity = 75.61%, speci city = 93.67%) 38 . Similarly, the AUC of another four-miRNA panel, containing miR-18a-5p, miR-138-5p miR-141-3p, and miR-181b-5p, was 0.908 (95% CI: 0.852-0.948; sensitivity = 80.77%, speci city = 88.89%) 39 . Our study reported that the AUC of a three-miRNA panel for KIRC diagnosis, including miR-1-3p, miR-129-5p and miR-146b-5p, was 0.895(95% CI: 0.848 to 0.942; sensitivity = 89.30%, speci city = 76.19%).…”

Section: Discussionmentioning

confidence: 90%

A serum panel of three microRNAs may serve as a possible biomarker for Kidney renal clear cell carcinoma

Wen

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Approximately 75 percent of cases of renal cell carcinoma, also known as kidney renal clear cell carcinoma (KIRC), are diagnosed during procedures to identify renal cell carcinoma (RCC). Although non-invasive radiological techniques are widely applied in the diagnoses of KIRC, ˃ 50% of KIRCs are currently detected incidentally. The presence of microRNA (miRNA) in serum has the potential to serve as a non-invasive diagnostic biomarker for KICC. Method: In the three-part trial, there were a total of 224 participants, 112 of them were KIRC patients (KIRCs), while the other 112 were healthy controls (NCs). RT-qPCR was utilized so that we could evaluate the level of miRNA expression in both KIRCs and NCs. ROC curves and the area under the ROC curve (AUC) were utilized in order to make a prediction regarding the usefulness of serum miRNAs for KIRC diagnosis. In addition, we performed survival analysis and bioinformatics with our research. Results: We discovered that miR-1-3p, miR-129-5p, miR-146b-5p, miR-187-3p and miR-200a-3p showed statistically significant differences when compared to NCs. It was determined that a panel consisting of three microRNAs (miR-1-3p, miR-129-5p and miR-146b-5p) had an AUC of 0.895, with a 95% confidence interval ranging from 0.848 to 0.942. CREB5 may be a potential target gene of the panel in the GEPIA database. According to the survival analysis, the overexpression of miR-146b-5p was indicative of a poorer prognosis for KIRC patients. Conclusions:There is a significant possibility that the three-miRNA panel in the serum could serve as non-invasive indicators for KIRC.

show abstract

Section: Discussionmentioning

confidence: 90%

A serum panel of three microRNAs may serve as a possible biomarker for Kidney renal clear cell carcinoma

Wen

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The AUC of a four-miRNA panel for RCC diagnosis containing miR-1-3p, miR-155-5p, miR-200b-3p, and miR-224-5p was 0.903 (95% CI 0.847–0.944; p < 0.001; sensitivity = 75.61%; specificity = 93.67%) [ 44 ]. Similarly, the AUC of another four-miRNA panel, containing miR-18a-5p, miR-138-5p, miR-141-3p, and miR-181b-5p, was 0.908 (95% CI 0.852–0.948; sensitivity = 80.77%, specificity = 88.89%) [ 45 ]. In our study, the AUC of a three-miRNA panel, including miR-1-3p, miR-129-5p, and miR-146b-5p, for KIRC diagnosis, was 0.895 (95% CI 0.848 to 0.942; sensitivity = 89.30%, specificity = 76.19%).…”

Section: Discussionmentioning

confidence: 99%

A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma

Wen,

Li,

Zhao

et al. 2024

Cancer Cell Int

Self Cite

View full text Add to dashboard Cite

Background Although non-invasive radiological techniques are widely applied in kidney renal clear cell carcinoma (KIRC) diagnosis, more than 50% of KIRCs are detected incidentally during the diagnostic procedures to identify renal cell carcinoma (RCC). Thus, sensitive and accurate KIRC diagnostic methods are required. Therefore, in this study, we aimed to identify KIRC-associated microRNAs (miRNAs). Methods This three-phase study included 224 participants (112 each of patients with KIRC and healthy controls (NCs)). RT-qPCR was used to evaluate miRNA expression in KIRC and NC samples. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were used to predict the usefulness of serum miRNAs in KIRC diagnosis. In addition, we performed survival and bioinformatics analyses. Results We found that miR-1-3p, miR-129-5p, miR-146b-5p, miR-187-3p, and miR-200a-3p were significantly differentially expressed in patients with KIRC. A panel consisting of three miRNAs (miR-1-3p, miR-129-5p, and miR-146b-5p) had an AUC of 0.895, ranging from 0.848 to 0.942. In addition, using the GEPIA database, we found that the miRNAs were associated with CREB5. According to the survival analysis, miR-146b-5p overexpression was indicative of a poorer prognosis in patients with KIRC. Conclusions The identified three-miRNA panel could serve as a non-invasive indicator for KIRC and CREB5 as a potential target gene for KIRC treatment.

show abstract

“…miRNAs directly secreted into the plasma by RCC tumor or stromal cells have also been proven to be stable in humans and were reliably isolated via RT-qPCR of a centrifuged miRNA phase [16][17][18]. Serum represents another ideal biofluid for miRNA isolation in RCC, with numerous protocols describing the isolation of multiple miRNA targets via RT-qPCR of human serum, showing the reliability of the biofluid as a substrate for the design of diagnostic panels [19][20][21][22][23]. Techniques for the isolation of exosomal miRNA from the serum of patients affected by ccRCC have also been presented, including the use of antibody-conjugated magnetic beads for exosome extraction [24,25].…”

Section: Mirna Isolationmentioning

confidence: 99%

The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature

et al. 2022

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most common form of kidney cancer with 403,262 diagnoses and 170,000 deaths worldwide in 2018. Although partial or radical nephrectomy can be considered a successful treatment in early-stage or localized RCC, in advanced-stage disease, there is a high risk of metastasis or recurrence with a significantly poorer prognosis. Metastatic RCC is generally resistant to both chemotherapy and radiotherapy, and, despite several novel therapeutic agents, disease progression and mortality rates remain high. It is necessary to identify new diagnostic and therapeutic strategies for the management of this cancer. Knowledge of microRNA (miRNA) has consistently increased in the last year. miRNAs play an important role in several biological processes, such as cell proliferation, differentiation, and cell death. Due to this, miRNAs have been identified as an important key in different diseases, especially in cancer, and several studies show miRNAs as attractive tools and targets for novel therapeutic approaches. Recently several miRNAs (including miR-22, miR-203, miR-301 and miR-193a-3p) have been linked to dysregulated molecular pathways involved with the proliferation of cancerous cells and resistance to therapeutic agents. In the present study, recent data from studies assessing the application of miRNAs as biomarkers, therapeutic targets, or modulators of response to treatment modalities in RCC patients are analyzed.

show abstract

A Four-MicroRNA Panel in Serum as a Potential Biomarker for Screening Renal Cell Carcinoma

Cited by 4 publications

References 59 publications

A serum panel of three microRNAs may serve as a possible biomarker for Kidney renal clear cell carcinoma

A serum panel of three microRNAs may serve as a possible biomarker for Kidney renal clear cell carcinoma

A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma

The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature

Contact Info

Product

Resources

About